Highlights from the ASGCT 23rd Annual Meeting
First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results
Steven Pipe1, Charles R. M. Hay2, John P. Sheehan3, Toshko Lissitchkov4, Elke Detering5, Silvia Ribeiro5, Konstantina Vanevski5
1University of Michigan, Ann Arbor, MI
2University Dept of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom
3Department of Medicine, University of Wisconsin–Madison, Madison, WI
4National Specialized Hospital for Active Treatment of Haematologic Diseases, Sofia, Bulgaria
5Bayer, Basel, Switzerland
RELATED CONTENT
Interactive Webinars
Podcasts